Determinants of lung function improvement with omalizumab in adults with allergic asthma
Publication date: Available online 22 January 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Nicola A. Hanania, Ratko Djukanovic, Liam G. Heaney, Ming Yang, Bongin Yoo, Ahmar Iqbal, Noelle M. Griffin, Bradley E. Chipps
ConclusionsThese survey results suggest that the PLLR format was not known by a majority of prescribers and that the pregnancy letter category format is continuing to be used despite significant flaws in the old system. However, the survey did not address why prescribers were continuing to rely on the pregnancy letter category system. Whether this is due to the PLLR format itself or the lack of quality data to inform the safe use of medications in pregnancy cannot be determined from these survey results. FDA will use these survey results to refine the communication of pregnancy safety information in labeling and will expan...
ConclusionsResults of real-time telemedically delivered asthma education to improve QOL, enhance symptom management ability, and reduce symptom burden were positive or non-significant. No study indicated negative effects due to telemedicine. Limited results indicate that patient education can, under certain circumstances, positively influence asthma burden. Further validation of intervention methods and tools as well as outcome measurement consistency is recommended.
Publication date: Available online 18 February 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Ryobu Mori, Hisako Matsumoto, Shigeo Muro, Hiroko Morisaki, Ryozo Otsuki
ConclusionEczema phenotypes were differentially associated with risks of respiratory and allergic conditions in school-aged children. Children with early transient and persistent eczema might benefit from more intense follow-up for early identification and treatment of asthma and allergies.
Infants in homes with frequent cleaning product use have increased odds for childhood wheeze, asthma
Asthma is a severe and chronic disabling disease affecting more than 300 million people world-wide. While in the past few drugs for treatment of asthma were available, new treatment options are currently emerging which appear to be highly effective in certain subgroups of patients. Accordingly there is a need for biomarkers which allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on micro-arrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed which may discriminate two of the most common forms of asthma, ...
In our recent report we studied associations between early-life exposure to individual bacterial genera of the indoor microbiota and the development of asthma.1 In a correspondence to this report, Fu et al2 compliment our novel approach, but question some of the statistical choices made and ask for a new sensitivity analysis.
Increasing evidence indicates that the development of asthma is associated with microbial communities in indoor environments.1,2 However, because of high temporal and spatial variations and the multidimensionality of microbiome data set, it is challenging to identify an accurate set of protective and risk microbes for asthma. The current standard is performing association analysis between asthma and microbial community composition or quantity of cellular components (eg, endotoxins or microbial volatile organic compounds).
While mepolizumab improves health-related quality of life and reduces exacerbation frequency in patients with severe eosinophilic asthma (SEA), those with SEA and nasal polyposis have a clinical phenotype that exhibits enhanced benefit with mepolizumab treatment.